Cyclo Therapeutics, Inc.

CYTH

US23254X2018

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
1.2 ^USD	-4.76%		-4.76%	-24.53%

06-11	Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.	CI
05-30	Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	CI

CTD Holdings Inc. Provides Earnings Guidance for the First Quarter Ended March 31, 2012

May 16, 2012 at 11:38 am

CTD Holdings Inc. provided earnings guidance for the first quarter ended March 31, 2012. The company announced that it will report record revenue of $441,909 for the quarter. In addition, the company will be reporting positive net income for the quarter.

Latest news about Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.	06-10	CI
Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	05-30	CI
Cyclo Therapeutics Files $100 Million Mixed Shelf	05-24	MT
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target	05-01	MT
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	03-14	MT
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	12-27	MT
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	12-27	CI
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	12-26	CI
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	12-18	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	11-10	MT
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	11-10	MT
Top Premarket Decliners	11-10	MT
Cyclo Therapeutics, Inc. announced that it has received $2.147009 million in funding	23-10-19	CI
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ
Maxim Upgrades Cyclo Therapeutics to Buy From Hold With $4 Price Target	23-09-27	MT
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge	23-09-21	MT
Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board	23-08-21	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.	23-08-01	CI
Cyclo Therapeutics Says European Patent Office Grants Allowance of Trappsol Cyclo Patent; Shares Rise	23-06-12	MT
Cyclo Therapeutics Signs $5 Million Funding Deal with Rafael Holdings	23-06-05	MT
Cyclo Therapeutics, Inc. announced that it expects to receive $5 million in funding from Rafael Holdings, Inc.	23-05-31	CI

Chart Cyclo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Companyâs Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimerâs disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimerâs disease (NCT03624842).

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cyclo Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.2 USD

Average target price

3.2 USD

Spread / Average Target

+166.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CYCLO THERAPEUTICS, INC.	-24.53%	34.34M
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B

Other Pharmaceuticals

Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Pharmaceuticals

CTD Holdings Inc. Provides Earnings Guidance for the First Quarter Ended March 31, 2012

EPS Revisions